Trial record 12 of 159 for:    Open Studies | "Lung Diseases, Interstitial"

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2012 by University of Chicago
Sponsor:
Collaborator:
Idiopathic Pulmonary Fibrosis Clinical Research Network
Information provided by (Responsible Party):
Imre Noth, University of Chicago
ClinicalTrials.gov Identifier:
NCT00470327
First received: May 3, 2007
Last updated: September 13, 2012
Last verified: September 2012
  Purpose

The purpose of this study is to obtain information on all patients being cared for by the ILD program in an effort to better understand the natural course of these diseases. Hopefully getting this information will lead to a better understanding of how these diseases behave with time. This in turn, will let physicians' better treat patients in the future.

Another goal of the study is to be able to see if in the future a patients' genetics can be linked to the type of disease they have and the way it behaves. We do not yet know what that may be. Our goal is to study this in aggregate rather than in any individual patients. Which genes to study are also unclear. But the only hope of having a clearly defined group to match the genetics to in the future requires that we obtain samples now in conjunction with collecting the data on the disease progression.


Condition
Interstitial Lung Diseases
Idiopathic Pulmonary Fibrosis
Sarcoidosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Study of the Natural Progression of Interstitial Lung Disease (ILD)

Resource links provided by NLM:


Further study details as provided by University of Chicago:

Biospecimen Retention:   Samples With DNA

blood


Estimated Enrollment: 4000
Study Start Date: September 2005
Estimated Study Completion Date: December 2025
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Subjects cared for in the ILD (Interstitial Lung Disease)clinic

Criteria

Inclusion Criteria:

  • Interstitial lung disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00470327

Contacts
Contact: Spring Holland 773-834-4053

Locations
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Principal Investigator: Imre Noth, MD         
Sponsors and Collaborators
University of Chicago
Idiopathic Pulmonary Fibrosis Clinical Research Network
Investigators
Principal Investigator: Imre Noth University of Chicago
  More Information

No publications provided

Responsible Party: Imre Noth, Associate Professor, University of Chicago
ClinicalTrials.gov Identifier: NCT00470327     History of Changes
Other Study ID Numbers: 14163A
Study First Received: May 3, 2007
Last Updated: September 13, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Chicago:
Interstitial lung diseases
idiopathic pulmonary fibrosis
Sarcoidosis
mRNA and cytokine expression

Additional relevant MeSH terms:
Lung Diseases, Interstitial
Fibrosis
Lung Diseases
Pulmonary Fibrosis
Sarcoidosis
Idiopathic Pulmonary Fibrosis
Pathologic Processes
Respiratory Tract Diseases
Lymphoproliferative Disorders
Lymphatic Diseases
Idiopathic Interstitial Pneumonias

ClinicalTrials.gov processed this record on August 20, 2014